BeiGene, Ltd. Insider Trading for February 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BeiGene, Ltd..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BeiGene, Ltd. for February 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Merck & Co., Inc. | 10% Owner | Option Exercise | C | 0.00 | 5,128,205 | 0 | 0 | |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Merck & Co., Inc. | 10% Owner | Option Exercise | C | 0.00 | 18,518,519 | 0 | 0 | |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Merck & Co., Inc. | 10% Owner | Buy | J | 0.00 | 7,942,314 | 0 | 7,942,314 | 0 to 7.9 M |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Merck & Co., Inc. | 10% Owner | Buy | C | 0.00 | 5,128,205 | 0 | 5,128,205 | 0 to 5.1 M |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Merck & Co., Inc. | 10% Owner | Buy | C | 0.00 | 18,518,519 | 0 | 18,518,519 | 0 to 18.5 M |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Hillhouse Capital Management, ... | 10% Owner | Option Exercise | C | 0.00 | 15,811,965 | 0 | 0 | |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Hillhouse Capital Management, ... | 10% Owner | Option Exercise | C | 0.00 | 14,814,814 | 0 | 0 | |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Hillhouse Capital Management, ... | 10% Owner | Buy | P | 0.00 | 9,100,000 | 0 | 39,726,779 | 30.6 M to 39.7 M (+29.71 %) |
| Feb 10 2016 | BGNE | BeiGene, Ltd. | Hillhouse Capital Management, ... | 10% Owner | Buy | C | 0.00 | 30,626,779 | 0 | 30,626,779 | 0 to 30.6 M |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.68 | 56,853 | 38,376 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.68 | 2,296,890 | 1,550,401 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.68 | 238,850 | 161,224 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 26,292,961 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 1,912,167 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 582,747 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 44,572,171 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 4,382,118 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 24.00 | 1,723,306 | 41,359,344 | 1,723,306 | 0 to 1.7 M |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 24.00 | 189,374 | 4,544,976 | 189,374 | 0 to 189.4 K |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.68 | 56,853 | 38,376 | 639,600 | 582.7 K to 639.6 K (+9.76 %) |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.68 | 2,296,890 | 1,550,401 | 73,162,022 | 70.9 M to 73.2 M (+3.24 %) |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.68 | 238,850 | 161,224 | 6,533,135 | 6.3 M to 6.5 M (+3.79 %) |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 26,292,961 | 0 | 70,865,132 | 44.6 M to 70.9 M (+58.99 %) |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 1,912,167 | 0 | 6,294,285 | 4.4 M to 6.3 M (+43.64 %) |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 582,747 | 0 | 582,747 | 0 to 582.7 K |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 44,572,171 | 0 | 44,572,171 | 0 to 44.6 M |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 4,382,118 | 0 | 4,382,118 | 0 to 4.4 M |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | OYLER JOHN | CEO | Option Exercise | C | 0.00 | 9,398,380 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | OYLER JOHN | CEO | Option Exercise | X | 0.00 | 57,777 | 0 | 9,398,380 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | OYLER JOHN | CEO | Option Exercise | X | 0.68 | 57,777 | 38,999 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | OYLER JOHN | CEO | Buy | C | 0.00 | 9,398,380 | 0 | 59,780,349 | 50.4 M to 59.8 M (+18.65 %) |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | Chen Timothy Yung-Cheng | Director | Option Exercise | A | 2.43 | 460,626 | 1,119,321 | 460,626 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | Liang Howard | CFO & Chief Strateg ... | Buy | P | 1.85 | 65,000 | 120,250 | 65,000 | 0 to 65 K |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | Yuan RuiRong | Chief Medical Offic ... | Buy | P | 1.85 | 130,000 | 240,500 | 130,000 | 0 to 130 K |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | CB Biotech Investment Ltd | 10% Owner | Option Exercise | C | 0.00 | 4,786,324 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | CB Biotech Investment Ltd | 10% Owner | Option Exercise | C | 0.00 | 14,814,814 | 0 | 0 | |
| Feb 09 2016 | BGNE | BeiGene, Ltd. | CB Biotech Investment Ltd | 10% Owner | Buy | C | 0.00 | 19,601,138 | 0 | 19,601,138 | 0 to 19.6 M |